April 20, 2026 9:25–9:43 AM
Broadway 3
Annoviant is advancing patient outcomes in heart disease by delivering innovative, regenerative cardiovascular devices built on its proprietary TxGuard™ soft-tissue technology.
The platform enables durable, off-the-shelf solutions that address critical unmet needs in heart valve disease and coronary artery bypass grafting—helping patients live healthier lives while reducing long-term healthcare costs.
